The Pharma Letter3 天
GLP-1R gold rush: emerging biotechs set to challenge market leaders
The glucagon-like peptide-1 receptor (GLP-1R) market experienced significant growth in 2023, generating $37.2 billion in ...
Employee Benefit News8 天Opinion
The major factors that go into the decision to cover GLP-1s
As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two ...
Preserving muscle with GLP-1 weight loss drugs: Big deal or nothing to worry about?
Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is ...
From Davids to Goliaths: the GLP-1RA gold rush
There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.
From Davids to Goliaths: the GLP-1R gold rush
There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.